This trial is to study Acthar Gel in participants with active systemic lupus erythematosus (SLE). The doctor will assign eligible patients to one of two groups (like flipping a coin). Participants will receive the treatment assigned to their group for 24 weeks: * Acthar Gel * Placebo Gel, which looks like Acthar Gel, but has no medicine in it. The doctor or his staff will take measurements and ask questions to: * see how well the gel is working * see how safe it is for patients with SLE
This trial was initiated (started recruiting) in October 2016, but first patient was not enrolled (randomized) until December, 2016.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
172
1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)
1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
Physician's Global Assessment (PGA)
PGA is a 100 mm visual analogue scale where higher scores indicate more severe disease activity. Lower scores indicate improvement.
Time frame: Baseline, Week 16, Week 24
British Isles Lupus Assessment Group 2004 (BILAG 2004)
BILAG records disease activity occurring over the past 4 weeks, and is used to determine whether different course of treatment is required. The BILAG-2004 index covers 97 signs/symptoms across 9 organ systems. Each question is answered as 0-not present, 1-improving, 2-same, 3-worse, or 4-new. The BILAG-2004 index categorizes disease activity in each organ system into five different levels from A to E. Grade A represents very active disease, Grade B represents moderate disease activity, Grade C indicates mild stable disease, and grade D implies no disease activity, but suggests the organ system had previously been affected. Grade E indicates no current or previous disease activity. A score is applied to each grade of each organ system using coding scheme of A=12, B=8, C=1, and D/E=0 and is summarized as a total score ranging 0-108. Higher scores indicate more severe disease activity.
Time frame: Baseline, Week 16, Week 24
Number of Participants With at Least a 4 Point Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K)
The SLEDAI-2K is a modified version of a composite score based on the presence or absence of clinical signs, clinical symptoms, and immunologic laboratory results taken within 10 days of the evaluations. Each of the descriptors has a weighted score and the total score of SLEDAI-2K is the sum of all 24 descriptor scores. The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity. Decrease from baseline indicates improvement.
Time frame: Week 16, Week 24
Number of Participants With Severe Flare, Based on the SELENA Flare Index (SFI) at Week 16
Among some adults, having a period of SLE symptoms-called flares-may happen every so often, sometimes even years apart, and go away at other times-called remission. The SFI categorizes SLE flares as mild, moderate or severe.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
C.V. Mehta MD Medical Corporation
Hemet, California, United States
Inland Rheumatology Clinical Trials
Upland, California, United States
Center for Rheumatology Immunology and Arthritis
Fort Lauderdale, Florida, United States
San Marcus Research Clinic
Miami, Florida, United States
Advanced Pharma CR
Miami, Florida, United States
Millennium Research
Ormond Beach, Florida, United States
Office of George Timothy Kelly MD
Las Vegas, Nevada, United States
NewYork-Presbyterian Columbia University Medical Center
New York, New York, United States
DJL Clinical Research
Charlotte, North Carolina, United States
Paramount Medical Research & Consulting
Middleburg Heights, Ohio, United States
...and 29 more locations
Time frame: Week 16
Mean Cutaneous Lupus Erythematosus Disease Area and Severity Score- Activity (CLASI) Total Activity Score
The CLASI total activity score reflects ongoing inflammation that can be treated, with points given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Mild, moderate, and severe disease correspond with CLASI activity score ranges of 0 to 9, 10 to 20, and 21 to 70, respectively. Higher scores indicate more disease activity, lower scores indicate improvement.
Time frame: at Baseline and Weeks 4, 8, and 16
Mean Number of Swollen or Tender Joints on the 28-Joint Count
The 28 Joint Count includes assessment of swelling and tenderness in the shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and knees. The investigator counts how many of the 28 joints are swollen or tender at the given week.
Time frame: at Baseline and at Weeks 4, 8, 12 and 16
Number of Participants With Decrease in Prednisone Dose to < 7.5 mg/Day at Week 20 and Week 24
Time frame: Week 20, Week 24